Transforming growth factor-beta (TGF-β) expression and interaction with proteinase 3 (PR3) in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis

Clinical and Experimental Immunology

Volumn 105, Issue 1, 1996, Pages 104-111

  Csernok, E ^a,c   Szymkowiak, C H ^a   Mistry, N ^a   Daha, M R ^b   Gross, W L ^a   Kekow, J ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Rheumaklinik Bad Bramstedt   (Germany)

Author keywords

anti neutrophil cytoplasmic antibodies; autoimmunity; proteinase 3; transforming growth factor beta; vasculitis

Indexed keywords

AUTOANTIGEN; INTERLEUKIN 1; INTERLEUKIN 6; NEUTROPHIL CYTOPLASMIC ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; AUTOIMMUNITY; CELL ISOLATION; CHEMOTAXIS; CHURG STRAUSS SYNDROME; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MODEL; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 0030056705     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.d01-715.x     Document Type: Article

References (44)

1. Wahl SM. Transforming growth factor β: the good, the had, and the ugly. J Exp Med 1994; 180:1587-90.
2. Kekow J, Wiedemann GJ. Transforming growth factor β: a cytokine with multiple actions in oncology and potential clinical applications. Int J Oncol 1995; 7:177-82.
3. Lotz M, Kekow J, Carson DA. Transforming growth factor-β and cellular immune responses in synovial fluids. J Immunol 1990; 144:4189-94.
4. Allen JB, Manthey CL, Hand AR, Ohura K, Ellingsworth L, Wahl SM. Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor β. J Exp Med 1990; 171:231-47.
5. Brandes ME, Allen JB, Ogawa Y, Wahl SM. TGF-β1 suppresses leukocyte recruitment and synovial inflammation in experimental arthritis. J Clin Invest 1991; 87:1108-13.
6. Gross WL, Schmitt WH, Csernok E. ANCA and associated diseases: Immuno-diagnostic and pathogenic aspects. Clin Exp Immunol 1993; 91:1-12.
7. Gross WL, Csernok E, Helmchen U. Antineutrophil cytoplasmic auto-antibodies, autoantigens, and systemic vasculitis. APMIS 1995; 103:81-97.
8. Kekow J, Szymkowiak C, Gross WL. Involvement of cytokines in granuloma formation within primary systemic vasculitis. In: Romagnani S, Mosmann TR, Abbas AK, eds. New advances on cytokines. New York: Raven Press, 1992:341-8.
9. Deguchi Y, Shibata N, Kishimoto S. Enhanced expression of the tumor necrosis factor/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis. Clin Exp Immunol 1990; 81:311-4.
10. Roux-Lombard P, Lin JM, Peter JB, Dayer JM. Elevated serum levels of TNF soluble receptors in patients with positive anti-neutrophil cytoplasmic antibodies. Br J Rheumatol 1994; 33:428-31.
11. Gross WL, Csernok E. Immunodiagnostic and pathophysiologic aspects of antineutrophil cytoplasmic antibodies in vasculitis. Curr Opin Rheumatol 1995; 7:11-19.
12. Kallenberg CGM, Cohen Tervaert JW, Van der Woude FJ, Goldschmeding R, van dem Borne AEGK, Weening JJ. Autoimmunity to lysosomal enzymes: new clues to vasculitis and glomerulonephritis. Immunol Today 1991; 12:61-64.
13. Gross WL, Csernok E, Flesch BK. 'Classic' anti-neutrophil cytoplasmic autoantibodies (cANCA), 'Wegener's autoantigen' and their immunopathogenic role in Wegener's granulomatosis. Auto-immunity 1993; 6:171-84.
14. Lüdemann J, Utecht B, Gross WL. Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme. J Exp Med 1990; 171:357-62.
15. Wahl SM. The role of transforming growth factor-beta in inflammatory processes. Immunol Res 1991; 10:249-54.
16. Roberts AB, Sporn MB, Assoian RK et al. Transforming growth factor type-beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986; 83:4167-71.
17. Szymkowiak C, Mons I, Gross WL, Kekow J. Determination of transforming growth factor-beta 2 in human blood samples by ELISA. J Immunol Methods 1995; 184:263-71.
18. Lyons RM, Gentry LE, Purchio AF, Moses HL. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol 1990; 110:1361-7.
19. Jeanette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Arthritis Rheum 1994; 37:187-92.
20. Lotz M, Tsoukas CD, Robinson CA, Dinarello CA, Carson DA, Vaughan JH. Basis for defective responses of rheumatoid arthritis synovial fluid lymphocytes to anti-CD3 (T3) antibodies. J Clin Invest 1986; 78:713-21.
21. Kekow J. Wachsman W, MacCutchan JA, Cronin M, Carson DA, Lotz M. Transforming growth factor β and noncytopathic mechanisms of immunodeficiency in human immunodeficiency virus infection. Proc Natl Acad Sci USA 1990; 87:8321-5.
22. Absher M, Baldor. L, Kelley J. A rapid colorimetric bioassay for transforming growth factor beta (TGF-beta) using a microwell plate reader. J Immunol Methods 1991; 138:301-3.
23. Kekow J, Wachsman W, Mc Cutchan JA et al. TGF-β and suppression of humoral immune responses in HIV infection. J Clin Invest 1991; 87:1010-6.
24. Csernok E, Lüdemann J, Gross WL, Bainton DF. Ultrastructural localization of proteinase 3, the target antigen of anti-cytoplasmic antibodies, circulating in Wegener's granulomatosis. Am J Pathol 1990; 137:1113-20.
25. Csernok E, Ernst M, Schmitt W, Bainton DF, Gross WL. Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol 1994; 95:244-50.
26. Leid RW, Ballieux BE, van der Heijden I et al. Cleavage and activation of human C1 inhibitor by the human leukocyte proteinase, proteinase 3. Eur J Immunol 1993; 23:2939-44.
27. Lyons RM, Keski-Oja J, Moses HL. Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J Cell Biol 1988; 106:1659-65.
28. Reinhold-Keller E, Kekow J, Schnabel A et al. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum 1994; 37:919-24.
29. Torre Amione G, Beauchamp RD, Koeppen H et al. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 1990; 87:1486-90.
30. Tatsis E, Reinhold-Keller E, Csernok E, Gross WL. Wegener's granulomatosis and malignancy: is there an association? Arthritis Rheum 1994; 37:S408.
31. Maeda J, Ueki N, Ohkawa T et al. Local production and localization of transforming growth factor-beta in tuberculous pleurisy. Clin Exp Immunol 1993; 92:32-38.
32. Gross WL, Hauschild S, Mistry N. The clinical relevance of ANCA in vasculitis. Clin Exp Immunol 1994; 93:7-11.
33. Samuel SK, Hurta RAR, Kondaiah P et al. Autocrine induction of tumor protease production and invasion by a metallothionein-regulated TGF-β1 (Ser223, 225). EMBO 1992; 11:1599-605.
34. Gross WL. New developments in the treatment of systemic vasculitis. Curr Opin Rheumatol 1994; 6:11-19.
35. Zhou D, Munster A, Winchurch RA. Pathologic concentrations of interleukin 6 inhibit T cell responses via induction of activation of TGF-β. FASEB 1991; 5:2582-5.
36. Cassatella MA. The production of cytokines by polymorphonuclear neutrophils. Immunol Today 1995; 16:21-26.
37. Schultz-Cherry S, Murphy-Ullrich JE. Thrombospondin causes activation of latent transforming growth factor-β secreted by endothelial cells by a novel mechanism. J Cell Biol 1993; 122:923-32.
38. Wahl SM. Transforming growth factor beta (TGF-beta) in inflammation: a cause and a cure. J Clin Immunol 1992; 12:61-74.
39. Roberts AB, Sporn MB. Transforming growth factor beta. Adv Cancer Res 1988; 51:107-45.
40. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994; 331:1286-92.
41. McCartney-Francis NL, Wahl SM. Transforming growth factor beta: a matter of life and death. J Leukoc Biol 1994; 55:401-9.
42. Wahl SM, Allen JB, Costa GL, Wong HL, Dasch JR. Reversal of acute and chronic synovial inflammation by anti-transforming growth factor β. J Exp Med 1993; 177:225-30.
43. Border WA, Noble NA, Yamamoto T et al. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 1992; 360:361-4.
44. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature 1990; 346:371-4.